Entering text into the input field will update the search result below

Novavax: NanoFlu Vaccine Exceeds Typical Expectations For Flu Treatment

Mar. 05, 2018 5:00 AM ETNovavax, Inc. (NVAX)10 Comments


  • Novavax announces positive phase 1/2 NanoFlu Vaccine results.
  • NanoFlu was able to show a superior immune response to currently approved standard vaccines for the H3N2 strain that has been responsible for 75% of this year's hospitalizations.
  • An interim update is expected by mid-2018 for Novavax's RSV vaccine candidate in phase 3 for treating maternal immunization of infants.
  • The financials are in okay shape, but it is highly likely that Novavax will have to raise more cash in the coming months.
  • Novavax has a good pipeline of candidates that could potentially eventually create shareholder value.

In after-hours trade on Wednesday, Novavax (NASDAQ:NVAX) announced positive phase 1/2 results for its NanoFlu Vaccine. This positive data sat really well with investors and the stock jumped as much as 28% on the news with higher volume. The reason why the stock has reacted so much to this data is not only because the study was positive. It was able to achieve much higher responses against several flu strains compared to already FDA approved products. With positive phase 1/2 NanoFlu data, and more catalysts approaching in 2018 I would rank it as an excellent buy. This despite the fact that it has since traded lower. I believe it presents a great buying opportunity. Especially with interim data on the way in mid-2018 from a phase 3 study.

Phase 1/2 Data

The phase 1/2 NanoFlu study recruited a total of 330 patients who had to be 60 years of age or older. This study with NanoFlu showed a positive outcome against many strains of the flu virus of this season that caused a lot of hospitalizations. The virus responsible for this years problems is known as the H3N2 flu strain. This strain was responsible for 75% of the hospitalizations due to the flu virus. Why is this substantial? The reason being that this is the worst flu season on record. To make matters worse, the currently approved flu vaccines available to treat this strain are only 10% effective. So this goes back to Novavax's NanoFlu vaccine, and the reason why it jumped by more than 28% on this news. That is because it was able to show that the vaccine was 47% to 64% more effective against a variety of strains of the H3N2 compared to standard flu vaccines. Here are some of the H3N2 strains in which NanoFlu performed better in compared to standard vaccines:

Authors Note: Novavax was discussed in more depth with members of my private investing community Biotech Analysis Central

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical investment research service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to my Service, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers deep dive analysis of many pharmaceutical companies throughout the biotech sector. Come see for yourself if my service is right for you.

New Promotion Pricing: The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.

Author's note: To get these types of premium articles on attractive biotech and pharma stocks as soon as they are published, just click here for my profile. Hit the big orange "Follow" button and choose the real-time alerts option thank you for taking the time to read my analysis.

This article was written by

Terry Chrisomalis profile picture
Actionable ideas on small-large cap biotech stocks through deep analysis.

I am the Founder of Biotech Analysis Central, A subscription service on Seeking Alpha's Marketplace. If you want to learn more about biotech investing or you want to check out my biotech analysis you can do so with a free 2-week trial to my service. Just hit the "Learn More" button on the bottom of the Marketplace Research Tab. I have a Bachelors of Applied Science Degree In Technology Management, Industrial and Business Services Management from St. Petersburg College Florida. I have been investing in biotech stocks for many years, and I prefer to invest as a long term investor. With that In mind I seek stocks that have long term value! I primarily Like to Invest In biotechnology stocks and I accept the risks. I Write for the Healthcare Sector and Stock market in general. I contribute to Seeking Alpha.

You can follow me on stocktwits.com under the name BiopharmaPro where I currently have (62.5K) followers. Join me in my quest to find the best biotechnology stocks that deliver results to help patients with new treatment options.

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.